Search

The Next-Generation Clinical Research and Data Science Core monitors clinical and research activities of all Center sites, including Massachusetts Eye and Ear Infirmary (MEE), Massachusetts General Hospital (MGH), University of Utah (UofU), and University of California San Francisco (UCSF). The Core...

POSTDOCTORAL FELLOWSHIP IN DECISION MODELING AND CANCER SURVIVORSHIP The Division of General Pediatrics at Boston Children’s Hospital is seeking a highly motivated and capable decision scientist, epidemiologist or outcomes researcher with an interest in cancer prevention and survivorship. The fellow...

Harvard/MIT Equitable Access to Research Training (HEART) MD-PhD Summer Program The HEART MD-PhD Summer Program is a specialty track within SHURP focused on students interested in MD-PhD training, founded by current students in Harvard's MD-PhD program. Mission Statement: The HEART MD-PhD Summer...

DOWNLOAD FULL ISSUE Inclusion, Diversity, and Equity at Harvard Ophthalmology In the latest issue of Eye Witness, we highlight our latest efforts on inclusion, diversity, and equity, including our EYE CAN program, a multi-tiered framework created by our IDE leaders that aims to increase diversity...

Date Speaker Monday, December 5, 2022 Christopher Burd, MS, PhD. (Yale, CT) Host: Wayne Lencer, MD. Monday, January 9, 2023 Nicholas Zachos, PhD. (Nashville, TN) Host: Jerrold Turner, MD, PhD. Monday, March 6, 2023 Marcia B. Goldberg, MD. (MGH, HMS) Host: Wayne Lencer, MD. Monday, April 3, 2023 Ruth...

Tuesday, May 23, 2023 - More info will be posted soon

Dear Colleagues, Research in gene augmentation and genome editing for the treatment of inherited retinal disorders (IRDs) is thriving. It is estimated that IRDs affect about 200,000- 300,000 people in the United States and 4-6 million people worldwide. Most patients with these conditions become...

Gene-Augmentation Therapy Gene therapy typically refers to gene-augmentation therapy. In this approach, a healthy version of the mutated gene is packaged inside an engineered and nonpathogenic form of adeno-associated virus (AAV), with the virus serving as a vector to carry the gene. AAV does not...

Advances in the future may include viral vectors, non-viral vectors, and delivery methods that allow treatment of a greater retinal expanse and an expanded approach to technical challenges related to gene size and disease mechanisms. Genetic therapies for non-retinal ophthalmic diseases are also...